An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage

Cerebral vasospasm and the resulting cerebral ischemia occurring after subarachnoid hemorrhage (SAH) are still responsible for the considerable morbidity and mortality in patients affected by cerebral aneurysms. Mechanisms contributing to the development of vasospasm, abnormal reactivity of cerebral arteries and cerebral ischemia after SAH have been intensively investigated in recent years. It has been suggested that the pathogenesis of vasospasm is related to a number of pathological processes, including endothelial damage, smooth muscle cell contraction resulting from spasmogenic substances generated during lyses of subarachnoid blood clots, changes in vascular responsiveness and inflammatory or immunological reactions of the vascular wall.A great deal of experimental and clinical research has been conducted in an effort to find ways to prevent these complications. However, to date, the main therapeutic interventions remain elusive and are limited to the manipulation of systemic blood pressure, alteration of blood volume or viscosity, and control of arterial dioxide tension.Even though no single pharmacological agent or treatment protocol has been identified which could prevent or reverse these deadly complications, a number of promising drugs have been investigated. Among these is the hormone erythropoietin (EPO), the main regulator of erythropoiesis. It has recently been found that EPO produces a neuroprotective action during experimental SAH when its recombinant form (rHuEPO) is systemically administered.This topic review collects the relevant literature on the main investigative therapies for cerebrovascular dysfunction after aneurysmal SAH. In addition, it points out rHuEPO, which may hold promise in future clinical trials to prevent the occurrence of vasospasm and cerebral ischemia after SAH.     

Petrous internal carotid aneurysm causing epistaxis: balloon embolization with preservation of the parent vessel

Summary A patient with severe, recurrent posterior epistaxis was shown at angiography to have an aneurysm of the petrous portion of the internal carotid artery (ICA). Since childhood, she had had pain related to eustachian tube blockage by the aneurysm. An endovascular balloon embolization of the aneurysm was successful with preservation of the parent artery. The treatment resulted in resolution of the symtpoms. The report confirms the usefulness of an angiographic protocol in evaluating vascular problems.     

重症脑出血微创术后下呼吸道感染病原学分析

目的:重症脑出血微创术后气管切开病人痰培养病原菌分布与耐药情况分析,其院内感染发生的原因、探讨防治对策。方法:应用痰培养检出的病原菌及耐药性分析。结果:重症脑出血微创术后气管切开病人下呼吸道感染41例,其中G-杆菌26例占63.4%,G 球菌15例占36.6%,其中金葡菌11例,药敏仍以敏感菌株为主,但耐药菌株有增多趋势。结论:重症脑出血微创术后气管切开病人下呼吸道感染以G-杆菌为主,G 球菌以金葡菌为主,仍以敏感菌珠为主,耐药有增多趋势。万古霉素对G 球菌,氨曲南对G-杆菌敏感性较敏感,故在培养结果未出来之前经验用药是非常重要的。     

颅内假性动脉瘤的手术治疗

目的探讨颅内假性动脉瘤的诊断和手术方法。方法回顾性分析16例手术治疗的颅内假性动脉瘤病人的临床及影像学特点．其中创伤性9例，感染性7例。结果出院时临床状况优良11例，轻残3例，死亡2例（其中1例为创伤性，术后发生脑梗死）。对12例行3个月。5年门诊随访，均未发生再出血。结论颅内假性动脉瘤是颅内动脉瘤中特殊且较复杂的类型，其诊断和处理策略与一般动脉瘤不同。提高对颅内假性动脉瘤的认识，以及有效应用神经外科技术，可以降低假性动脉瘤的手术风险，改善预后。     

骨桥蛋白在人脑动静脉畸形的表达及意义

目的研究骨桥蛋白(OPN)在脑动静脉畸形(CAVM)的血管组织及其在放射、栓塞治疗后血管病理变化中的表达。方法采用免疫组化方法检测42例CAVM病理标本及对照组10例内减压手术所获脑组织血管中OPN的表达。结果26例无术前治疗史的畸形血管组织中22例有OPN的表达,主要见于CAVM的静脉部分,在粥样硬化样病变的动脉处也有表达。对照组脑组织的血管中未见OPN的表达;有伽玛刀治疗史的5例中,2例在早、中期放射反应的动脉中可见OPN的明显表达;在经历栓塞治疗的11例中,7例在新生内膜组织或异物巨细胞中有强阳性表达。结论人CAVM血管组织中多有OPN的表达,这可能是其适应于适应血流动力学状态而具有的血管重塑的表现,并可能在放射及栓塞治疗后的血管重塑中发挥重要作用。     

磁场治疗白兔脑出血的安全性及疗效的实验研究

目的　探讨磁场治疗对实验性脑出血的治疗作用和安全性。方法　实验一 :5 0只大耳白兔被钩破大脑中动脉以建立脑出血模型。用CT扫描和解剖的方法观察脑出血的情况。实验二 :45只大耳白兔随机分为 0 .4T组、0 .8T组和对照组 ,每组 15只。每只白兔均采用实验一的方法建成脑出血模型。磁疗前CT扫描观察出血情况 ,磁疗后CT扫描观察血肿吸收情况。结果　实验一 :5 0只大耳白兔大脑中动脉钩破术后均出现对侧后下肢无力 ,肌张力降低 ,回缩反射减弱或消失。CT和解剖证实有脑出血。实验二 :45只大耳白兔均成功建成脑出血模型。磁疗前CT扫描 3组之间脑出血差异无显著性意义 (P >0 .0 5 ) ;磁疗后CT扫描 2磁疗组之间血肿吸收差异无显著性意义 (P >0 .0 5 ) ,与对照组比较血肿吸收差异有显著性意义 (P <0 .0 1)。结论　用钩破兔大脑中动脉的方法可建立脑出血动物模型。磁场治疗可促进实验性白兔脑出血的血肿吸收 ,且不产生继发性脑出血     

三维CT脑血管造影在脑动脉瘤诊断中注意点

目的探讨三维CT脑血管造影(3D-CTA)在诊断脑动脉瘤时的注意事项。方法回顾总结3D-CTA检查的106例蛛网膜下腔出血(SAH)病例,其中14例初次3D-CTA显示动脉瘤不清或发现颅内非动脉瘤样血管异常者,对其进行DSA脑血管造影检查。结果初次3D-CTA检查正确诊断脑动脉瘤92例,其中16例为多发脑动脉瘤,共检出115个。余14例因诊断不明确进而实施DSA脑血管造影检查,其中确诊动脉瘤合并烟雾病2例、严重脑血管痉挛致动脉瘤显示不清2例、脑动静脉畸形1例(此5例与3D-CTA所见一致);在3D-CTA扫查范围外发现脑动脉瘤2例。对上述阳性诊断的99例进行手术,并得到证实。另7例在3D-CTA和DSA检查未发现引起SAH的原因病灶,给予保守治疗。结论在脑动脉瘤诊断中,3D-CTA具有较好的精确性。在判断动脉瘤与颅骨位置关系、操作的便捷性和经济性等方面明显优于DSA。在应用3D-CTA对脑动脉瘤进行诊断时,有必要根据患者和设备的具体情况进行个性化设计,方能减少漏诊、误诊。     

Giant intracranial aneurysm of the anterior communicating artery treated by direct surgery using A3–A3 side-to-side anastomosis and A3-RA graft-STA anastomosis

Summary We describe a giant aneurysm of the anterior communicating artery (ACoA) which was treated with a STA-RA graft-A3 bonnet bypass and A3–A3 side-to-side anastomosis. A giant and partially thrombosed ACoA aneurysm was partially coated 3 years before his current presentation, its gradual increase producing visual field disturbances. An A3–A3 side-to-side anastomosis and STA-RA graft-A3 bonnet bypass were performed. The aneurysm was dissected, and the thrombus removed under transient parent-artery occlusion. The aneurysmal neck was successfully clipped without encountering ischemic changes. This strategy may be useful for treating giant or thrombosed aneurysms in the region of the ACoA.     

脑梗死OCSP分型和预后

目的了解脑梗死患者OCSP临床分型的构成及不同亚型与预后及复发的关系。方法采用回顾性队列研究,登记2002年1月~2005年6月第四军医大学西京医院神经内科确诊的617例脑梗死患者,按照OCSP标准分型并进行随访,分析各亚型与预后及复发的关系。结果OCSP各亚型构成比分变为:TACI占7.3%,PACI23.3%,POCI6.0%,LACI63.4%,分型与预后明显相关,TACI的预后最差,POCI和LACI预后相对较好,PACI次之,卒中复发与分型无明显相关。结论OCSP分型作为一种脑梗死临床分型方法,可以为脑梗死的预后判断提供参考依据。     

TCD观察动脉瘤性SAH后脑血管痉挛的血流动力学改变

目的探讨动脉瘤性蛛网膜下腔出血(SAH)后脑血管痉挛的血流动力学改变。方法经CT、DSA证实为动脉瘤性SAH患者179例,床旁经颅超声多谱勒(TCD)在术前、术后1~3d、5~7d、9~11d、12~14d记录并分析大脑中动脉(M CA)的血流参数及频谱改变。结果M CA平均血流速度(Vm)于SAH后1~3d开始升高,5~7d、9~11d达到高峰;L I(血管痉挛指数)为3~6时预后良好;>6时可以出现神经系统功能损害,颅内压增高且有脑血管痉挛(CV S)者预后较差。结论TCD能无创、实时评价SAH后CV S的动态变化,可以推断SAH后CV S的严重程度及临床转归。